MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PRLD had $21,973K increase in cash & cash equivalents over the period. -$56,369K in free cash flow.

Cash Flow Overview

Change in Cash
$21,973K
Free Cash flow
-$56,369K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of mark...
    • Deferred revenue
    • Proceeds from issuance of common...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Accounts payable
    • Accrued expenses and other liabi...
    • Others

Cash Flow
2025-12-31
Net loss
-99,498
Depreciation and amortization
1,711
Noncash lease expense
1,534
Stock-based compensation
11,913
Amortization of premium and discount on marketable securities, net
371
Prepaid expenses and other current assets
197
Accounts payable
-3,918
Accrued expenses and other liabilities
-2,980
Deferred revenue
35,532
Long-term prepaid expenses and other long-term assets
0
Operating lease liabilities
28
Net cash used in operating activities
-56,302
Purchases of marketable securities
100,866
Proceeds from maturities of marketable securities
154,392
Purchases of property and equipment
67
Net cash provided by investing activities
53,459
Proceeds from issuance of common stock in connection with the securities purchase agreement
24,875
Payment of offering costs
0
Proceeds from issuance of common stock in connection with the exercise of stock options
16
Proceeds from the issuance of common stock under espp
150
Payment of withholding taxes related to stock-based compensation to employees
17
Principal payments on finance lease
208
Net cash provided by (used in) financing activities
24,816
Net increase (decrease) in cash and cash equivalents
21,973
Cash, cash equivalents and restricted cash at beginning of year
16,518
Cash, cash equivalents and restricted cash at end of year
38,491
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof marketable...$154,392K Proceeds from issuance ofcommon stock in...$24,875K Proceeds from theissuance of common stock...$150K Proceeds from issuance ofcommon stock in...$16K Net cash provided byinvesting activities$53,459K Net cash provided by(used in) financing...$24,816K Canceled cashflow$100,933K Canceled cashflow$225K Net increase(decrease) in cash and cash...$21,973K Canceled cashflow$56,302K Purchases of marketablesecurities$100,866K Purchases of property andequipment$67K Deferred revenue$35,532K Stock-based compensation$11,913K Depreciation andamortization$1,711K Noncash lease expense$1,534K Principal payments onfinance lease$208K Payment of withholdingtaxes related to...$17K Net cash used inoperating activities-$56,302K Canceled cashflow$50,690K Net loss-$99,498K Accounts payable-$3,918K Accrued expenses andother liabilities-$2,980K Amortization of premium anddiscount on marketable...$371K Prepaid expenses andother current assets$197K Operating leaseliabilities$28K

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc (PRLD)